Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension by lowering intra‑ocular pressure, and is administered as a single drop in the affected eye(s) once daily for long‑term pressure control.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost, a prostaglandin analog, is used to manage conditions characterized by elevated intra‑ocular pressure.

- Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. - Ocular hypertension: lowers eye pressure in patients at risk of developing glaucoma. - Pseudoexfoliative glaucoma: provides IOP reduction similar to primary open‑angle glaucoma.

Latanoprost may cause ocular and systemic reactions. Patients should be aware of both common and rare events.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris darkening: gradual brownish pigmentation. - Eye irritation: burning or stinging sensation. - Blurred vision: transient visual disturbance. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Paradoxical IOP increase: unexpected rise in pressure. - Corneal edema: swelling of the cornea affecting clarity.

Before using Monoprost, consider the following safety measures.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown excretion; exercise caution. - Contraindications: avoid in eyes with active infection or inflammation. - Monitor IOP: assess pressure response after 4–6 weeks of therapy. - Single‑dose vials: discard any remaining solution to prevent contamination. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may diminish IOP‑lowering effect. - Concurrent prostaglandin analogs: risk of additive ocular side effects. - Systemic carbonic anhydrase inhibitors: potential excessive IOP reduction; monitor closely.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive pressure‑lowering effect. - Alpha‑adrenergic agonist eye drops: may increase ocular irritation. - Systemic corticosteroids: possible reduction in therapeutic response.